Talk to our Consultant - US Diagnostic Labs Market Growing at 7.52% CAGR

US Diagnostic Labs Market Research Report: Forecast (2026-2032)

US Diagnostic Labs Market - By Test Type (Pathology, Radiology & Imaging), By Pathology Test Type (Clinical Chemistry, Hematology, Immunology & Serology, Microbiology, Histopathology & Cytopathology,... ... gy & Cytopathology, Molecular Diagnostics, Genetic Testing), By Radiology Type (X-Ray, Ultrasound, CT Scan, MRI, Mammography, PET-CT, Nuclear Imaging, Others), By Service Delivery Mode (Walk-in Testing, Home Sample Collection, Mobile Diagnostic Units), By Disease Type (Infectious Diseases, Oncology, Diabetes & Endocrinology, Cardiology, Neurology, Nephrology, Gastroenterology, Gynecology & Obstetrics, Respiratory Disorders, Orthopedics, Others), By End-User (Hospitals, Physician Clinics, Independent Diagnostic Centers, Corporate & Preventive Health Programs, Government & Public Healthcare Institutions), and others Read more

Healthcare
Feb 2026
Pages 135
Report Format: PDF, Excel, PPT

US Diagnostic Labs Market Report Key Takeaways:

Market size was valued at around USD34.24 billion in 2025 and is projected to reach USD56.88 billion by 2032. The estimated CAGR from 2026 to 2032 is around 7.52%, indicating strong growth.
By Test Type, the Pathology segment represented a significant share of about 67% in the US Diagnostic Labs Market in 2025.
By End-User, Hospitals seized a significant share of about 45% in the US Diagnostic Labs Market in 2025.
Leading Diagnostic Labs Companies in the US Market are Labcorp, Quest Diagnostics, Mayo Clinic Laboratories, ARUP Laboratories, Bio-Reference Laboratories, Kaiser Permanente Laboratories, Cleveland Clinic Laboratories, Northwell Health Labs, Ascension Clinical Laboratories, Intermountain Healthcare Laboratories, Exact Sciences, Guardant Health, Myriad Genetics, Ambry Genetics, and Others.

Market Insights & Analysis: US Diagnostic Labs Market (2026-32):

The US Diagnostic Labs Market size was valued at around USD34.24 billion in 2025 and is projected to reach USD56.88 billion by 2032. Along with this, the market is estimated to grow at a CAGR of around 7.52% during the forecast period, i.e., 2026-32.

Market expansion is driven by the structural dependence of the US healthcare system on laboratory-led clinical decision-making, preventive screening, and chronic disease monitoring. Diagnostics form the backbone of care delivery across inpatient, outpatient, and employer-sponsored healthcare frameworks.

Market dynamics are shaped by disease burden and testing intensity. According to the US Centers for Disease Control and Prevention, nearly 129 million Americans live with at least one chronic condition, while over 42% of adults have multiple chronic diseases, necessitating repeated pathology testing. Additionally, the Centers for Medicare & Medicaid Services reports that laboratory services represent one of the highest-volume reimbursed outpatient services, reinforcing stable revenue generation.

Additionally, according to the National Institutes of Health (NIH), in 2024, the agency invested approximately USD30 billion in medical research, supporting laboratory research programs, facility upgrades, and biomedical infrastructure nationwide, thereby strengthening long-term diagnostic and pathology capacity across the United States , with diagnostics accounting for a significant share. Likewise, AI-enabled pathology, high-throughput analyzers, and digital workflows have reduced cost-per-test while increasing processing capacity.

Moreover, manufacturing and infrastructure expansion further support growth. In 2024, the Biden–Harris Administration committed USD51 million to a Central Indiana Tech Hub, strengthening biotechnology innovation, workforce development, and demonstration facilities, which indirectly support future diagnostic laboratory expansion and skilled talent availability. Similarly, in 2024, Novartis announced a USD23 billion U.S. investment plan, including biologics and research facility expansion in North Carolina, reinforcing large-scale laboratory, analytical testing, and quality-control infrastructure growth . These greenfield developments strengthen logistics resilience, turnaround times, and nationwide testing scalability, anchoring long-term market growth.

US Diagnostic Labs Market Recent Developments:

2025 : Quest Diagnostics formed a joint venture with Corewell Health to build and operate a 100,000 sq. ft. laboratory in Michigan, expected to open in Q1 2027, strengthening regional diagnostic capacity while Quest manages both existing and new laboratory operations.
2026 : Labcorp announced the construction of a new central laboratory facility in Brownsburg, Indiana, aimed at expanding testing capacity, improving turnaround times, and strengthening nationwide diagnostic infrastructure through long-term operational investment.

US Diagnostic Labs Market Scope:

Category	Segments
By Test Type	Pathology, Radiology & Imaging
By Pathology Test Type	Clinical Chemistry, Hematology, Immunology & Serology, Microbiology, Histopathology & Cytopathology, Molecular Diagnostics, Genetic Testing
By Radiology Type	X-Ray, Ultrasound, CT Scan, MRI, Mammography, PET-CT, Nuclear Imaging, Others
By Service Delivery Mode	Walk-in Testing, Home Sample Collection, Mobile Diagnostic Units
By Disease Type	Infectious Diseases, Oncology, Diabetes & Endocrinology, Cardiology, Neurology, Nephrology, Gastroenterology, Gynecology & Obstetrics, Respiratory Disorders, Orthopedics, Others
By End-User	Hospitals, Physician Clinics, Independent Diagnostic Centers, Corporate & Preventive Health Programs, Government & Public Healthcare Institutions

US Diagnostic Labs Market Driver:

Structural Dependence on Pathology-Led Preventive Care

The market growth is driven by the reliance of the healthcare system on pathology-led preventive and chronic care diagnostics. According to the CDC, 38.4 million Americans have diabetes, 116 million have hypertension, and 94 million exhibit elevated cholesterol levels, all requiring routine blood and biochemical testing. These conditions demand recurring diagnostics rather than episodic imaging.

Additionally, federal screening mandates reinforce pathology demand. The US Preventive Services Task Force expanded recommendations for colorectal cancer, lipid disorders, hepatitis C, and prediabetes screening between 2023 and 2025. Similarly, Medicare reimbursement schedules show pathology tests generate significantly higher annual claim volumes than radiology procedures, ensuring consistent lab utilization.

Moreover, according to the US Centers for Disease Control and Prevention, about 7 in 10 US adults aged 50–75 are up to date with recommended colorectal cancer screening, underscoring broad participation in routine preventive diagnostics . These accelerate clinical adoption of advanced pathology tests, strengthen diagnostic accuracy, and expand test menus, cementing pathology as the dominant testing modality.

Market Segmentation
Introduction
1. Product Definition
2. Research Process
3. Assumptions
Executive Summary
US Diagnostic Labs Market Policies, Regulations, and Product Standards
US Diagnostic Labs Market Trends & Developments
US Diagnostic Labs Market Dynamics
1. Growth Factors
2. Challenges
US Diagnostic Labs Market Hotspot & Opportunities
US Diagnostic Labs Market Outlook, 2022-2032F
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Outlook
  1. By Test Type- Market Size & Forecast 2022-2032, USD Million
    1. Pathology
    2. Radiology & Imaging
  2. By Pathology Test Type- Market Size & Forecast 2022-2032, USD Million
    1. Clinical Chemistry
    2. Hematology
    3. Immunology & Serology
    4. Microbiology
    5. Histopathology & Cytopathology
    6. Molecular Diagnostics
    7. Genetic Testing
  3. By Radiology Type- Market Size & Forecast 2022-2032, USD Million
    1. X-Ray
    2. Ultrasound
    3. CT Scan
    4. MRI
    5. Mammography
    6. PET-CT
    7. Nuclear Imaging
    8. Others
  4. By Service Delivery Mode- Market Size & Forecast 2022-2032, USD Million
    1. Walk-in Testing
    2. Home Sample Collection
    3. Mobile Diagnostic Units
  5. By Disease Type - Market Size & Forecast 2022-2032, USD Million
    1. Infectious Diseases
    2. Oncology
    3. Diabetes & Endocrinology
    4. Cardiology
    5. Neurology
    6. Nephrology
    7. Gastroenterology
    8. Gynecology & Obstetrics
    9. Respiratory Disorders
    10. Orthopedics
    11. Others
  6. By End-User- Market Size & Forecast 2022-2032, USD Million
    1. Hospitals
    2. Physician Clinics
    3. Independent Diagnostic Centers
    4. Corporate & Preventive Health Programs
    5. Government & Public Healthcare Institutions
  7. By Region- Market Size & Forecast 2022-2032, USD Million
    1. Northeast
    2. South Atlantic
    3. Pacific
    4. West South Central
    5. East North Central
  8. By Company
    1. Competition Characteristics
    2. Market Share & Analysis
US Pathology Labs Market Outlook, 2022-2032
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Outlook
  1. By Pathology Test Type- Market Size & Forecast 2022-2032, USD Million
  2. By Radiology Type- Market Size & Forecast 2022-2032, USD Million
  3. By Service Delivery Mode- Market Size & Forecast 2022-2032, USD Million
  4. By Disease Type - Market Size & Forecast 2022-2032, USD Million
  5. By End-User- Market Size & Forecast 2022-2032, USD Million
  6. By Region- Market Size & Forecast 2022-2032, USD Million
US Radiology & Imaging Labs Market Outlook, 2022-2032
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Outlook
  1. By Pathology Test Type- Market Size & Forecast 2022-2032, USD Million
  2. By Radiology Type- Market Size & Forecast 2022-2032, USD Million
  3. By Service Delivery Mode- Market Size & Forecast 2022-2032, USD Million
  4. By Disease Type - Market Size & Forecast 2022-2032, USD Million
  5. By End-User- Market Size & Forecast 2022-2032, USD Million
  6. By Region- Market Size & Forecast 2022-2032, USD Million
US Diagnostic Labs Market Key Strategic Imperatives for Success & Growth
Competitive Outlook
1. Company Profiles
  1. Labcorp
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  2. Quest Diagnostics
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  3. Mayo Clinic Laboratories
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  4. ARUP Laboratories
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  5. Bio-Reference Laboratories
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  6. Kaiser Permanente Laboratories
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  7. Cleveland Clinic Laboratories
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  8. Northwell Health Labs
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  9. Ascension Clinical Laboratories
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  10. Intermountain Healthcare Laboratories
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  11. Exact Sciences
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  12. Guardant Health
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  13. Myriad Genetics
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  14. Ambry Genetics
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

Full Name*:

Company Name*:

Business Email*:

Country Name*:

Contact Number*:

Message:

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Buy Now

Inquire Before Buying